$0.98
+0.01 (+1.03%)
Open$0.97
Previous Close$0.97
Day High$0.99
Day Low$0.95
52W High$1.45
52W Low$0.70
Volume—
Avg Volume216.9K
Market Cap42.52M
P/E Ratio—
EPS$-0.33
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+3,721.4% upside
Current
$0.98
$0.98
Target
$37.45
$37.45
$24.30
$37.45 avg
$44.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.43M | 3.79M | 3.81M |
| Net Income | -14,241,160 | 783.4K | 928.9K |
| Profit Margin | -994.5% | 20.7% | 24.4% |
| EBITDA | -15,948,658 | 1.80M | 1.92M |
| Free Cash Flow | — | 820.9K | 949.0K |
| Rev Growth | — | +6.9% | +13.5% |
| Debt/Equity | — | 0.92 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |